Does Rallies show OVID 10-K and 10-Q filings?

Rallies organizes OVID SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.

Is OVID research on Rallies investment advice?

No. Rallies provides research, data, and educational context for OVID. It does not provide personalized investment advice.

OVID (Ovid Therapeutics Inc. Common Stock) Stock Analysis - SEC Filings

Ovid Therapeutics Inc. Common Stock (OVID) is a publicly traded Healthcare sector company. As of May 21, 2026, OVID trades at $2.36 with a market cap of $449.80M and a P/E ratio of 0.00. OVID moved -0.42% today. Year to date, OVID is +43.98%; over the trailing twelve months it is +724.71%. Its 52-week range spans $0.24 to $3.11. Analyst consensus is strong buy with an average price target of $5.33. Rallies surfaces OVID's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find OVID SEC filings?

Rallies organizes OVID SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

OVID Key Metrics

Key financial metrics for OVID
Metric	Value
Price	$2.36
Market Cap	$449.80M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$3.11
52-Week Low	$0.24
Volume	10
Avg Volume	0
Revenue (TTM)	$7.12M
Net Income	$-24.17M
Gross Margin	0.00%

Latest OVID News

Ovid Therapeutics Doses KCC2 Activator, Raises $60M PIPE, $53.9M Warrants, Ends Q1 with $165.6M — May 12, 2026
Ovid Therapeutics Tops Q4 Estimates with $0.06 EPS, Secures $81M Funding — Mar 18, 2026
Ovid Secures $60M Financing, Shows 7mg OV329 Safety and Clears OV4071 — Mar 18, 2026
Ovid Therapeutics Raises $60M Via Private Placement to Fund OV329 Expansion — Mar 18, 2026
Ovid Therapeutics to Present at Feb. 25, Mar. 4 and Mar. 11 Investor Conferences — Feb 25, 2026

Recent OVID Insider Trades

ALEXANDER MARGARET A. sold 11.66K (~$16.90K) on Feb 23, 2026.
Rona Jeffrey A sold 8.54K (~$12.38K) on Feb 23, 2026.
ALEXANDER MARGARET A. sold 5.28K (~$2.96K) on Feb 26, 2025.

OVID Analyst Consensus

8 analysts cover OVID: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $5.33.

Common questions about OVID

Where can I find OVID SEC filings?: Rallies organizes OVID SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show OVID 10-K and 10-Q filings?: Rallies organizes OVID SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is OVID research on Rallies investment advice?: No. Rallies provides research, data, and educational context for OVID. It does not provide personalized investment advice.